Joshua M. Eizen - 04 Nov 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Operating Officer and Chief Legal Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Issuer symbol
ANTX
Transactions as of
04 Nov 2025
Transactions value $
-$3,214
Form type
4
Filing time
06 Nov 2025, 18:12:08
Previous filing
28 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Eizen Joshua M Chief Operating Officer and Chief Legal Officer C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK /s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen 06 Nov 2025 0001949621

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale -$3.21K -2.82K -1.56% $1.14 177K 04 Nov 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025.
F2 Includes, in accordance with the original terms, (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSUs vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.
F3 Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.

Remarks:

Chief Operating Officer and Chief Legal Officer